Upgrade to SI Premium - Free Trial

Biogen (BIIB): Tweaking Estimates On Spinraza Sales - Nomura

January 22, 2018 7:25 AM
Nomura/Instinet analyst, Christopher Marai, reiterated his Neutral rating on shares of Biogen (NASDAQ: BIIB) and slightly cut numbers taking ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change Analyst PT Change

Next Articles